vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and BRANDYWINE REALTY TRUST (BDN). Click either name above to swap in a different company.
AVANOS MEDICAL, INC. is the larger business by last-quarter revenue ($180.9M vs $127.0M, roughly 1.4× BRANDYWINE REALTY TRUST). AVANOS MEDICAL, INC. runs the higher net margin — -0.7% vs -38.4%, a 37.7% gap on every dollar of revenue. On growth, BRANDYWINE REALTY TRUST posted the faster year-over-year revenue change (4.5% vs 0.7%). Over the past eight quarters, AVANOS MEDICAL, INC.'s revenue compounded faster (4.4% CAGR vs 0.7%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Brandywine Realty Trust is a Philadelphia-based real estate investment trust (REIT) that invests in office buildings in Philadelphia, Washington, D.C., and Austin, Texas.
AVNS vs BDN — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $127.0M |
| Net Profit | $-1.3M | $-48.8M |
| Gross Margin | 47.5% | — |
| Operating Margin | 1.4% | 1.2% |
| Net Margin | -0.7% | -38.4% |
| Revenue YoY | 0.7% | 4.5% |
| Net Profit YoY | 99.7% | -80.4% |
| EPS (diluted) | $-0.02 | $-0.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $127.0M | ||
| Q4 25 | $180.9M | $121.0M | ||
| Q3 25 | $177.8M | $121.4M | ||
| Q2 25 | $175.0M | $120.6M | ||
| Q1 25 | $167.5M | $121.5M | ||
| Q4 24 | $179.6M | $121.9M | ||
| Q3 24 | $170.4M | $131.8M | ||
| Q2 24 | $171.7M | $125.3M |
| Q1 26 | — | $-48.8M | ||
| Q4 25 | $-1.3M | $-36.7M | ||
| Q3 25 | $-1.4M | $-25.9M | ||
| Q2 25 | $-76.8M | $-88.7M | ||
| Q1 25 | $6.6M | $-27.0M | ||
| Q4 24 | $-397.3M | $-44.5M | ||
| Q3 24 | $4.3M | $-165.2M | ||
| Q2 24 | $1.8M | $30.2M |
| Q1 26 | — | — | ||
| Q4 25 | 47.5% | 61.3% | ||
| Q3 25 | 48.4% | 62.6% | ||
| Q2 25 | 52.6% | 62.4% | ||
| Q1 25 | 53.6% | 60.8% | ||
| Q4 24 | 54.6% | 61.2% | ||
| Q3 24 | 54.5% | 64.9% | ||
| Q2 24 | 55.7% | 63.1% |
| Q1 26 | — | 1.2% | ||
| Q4 25 | 1.4% | 22.8% | ||
| Q3 25 | 0.1% | 20.8% | ||
| Q2 25 | -42.6% | -34.3% | ||
| Q1 25 | 6.1% | 12.5% | ||
| Q4 24 | -233.0% | 18.0% | ||
| Q3 24 | 7.0% | -7.2% | ||
| Q2 24 | 3.7% | 15.5% |
| Q1 26 | — | -38.4% | ||
| Q4 25 | -0.7% | -30.3% | ||
| Q3 25 | -0.8% | -21.3% | ||
| Q2 25 | -43.9% | -73.5% | ||
| Q1 25 | 3.9% | -22.2% | ||
| Q4 24 | -221.2% | -36.5% | ||
| Q3 24 | 2.5% | -125.4% | ||
| Q2 24 | 1.0% | 24.1% |
| Q1 26 | — | $-0.28 | ||
| Q4 25 | $-0.02 | $-0.21 | ||
| Q3 25 | $-0.03 | $-0.15 | ||
| Q2 25 | $-1.66 | $-0.51 | ||
| Q1 25 | $0.14 | $-0.16 | ||
| Q4 24 | $-8.64 | $-0.25 | ||
| Q3 24 | $0.09 | $-0.96 | ||
| Q2 24 | $0.04 | $0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $36.2M |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | — |
| Total Assets | $1.1B | $3.6B |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $36.2M | ||
| Q4 25 | $89.8M | $32.3M | ||
| Q3 25 | $70.5M | $75.5M | ||
| Q2 25 | $90.3M | $122.6M | ||
| Q1 25 | $97.0M | $29.4M | ||
| Q4 24 | $107.7M | $90.2M | ||
| Q3 24 | $89.0M | $36.5M | ||
| Q2 24 | $92.2M | $30.4M |
| Q1 26 | — | — | ||
| Q4 25 | $90.3M | $2.6B | ||
| Q3 25 | $93.4M | $2.3B | ||
| Q2 25 | $95.7M | $2.3B | ||
| Q1 25 | $98.0M | $2.2B | ||
| Q4 24 | $125.3M | $2.2B | ||
| Q3 24 | $152.6M | $2.3B | ||
| Q2 24 | $164.9M | $2.2B |
| Q1 26 | — | — | ||
| Q4 25 | $778.2M | $792.7M | ||
| Q3 25 | $778.0M | $841.5M | ||
| Q2 25 | $776.3M | $879.8M | ||
| Q1 25 | $839.4M | $993.6M | ||
| Q4 24 | $828.5M | $1.0B | ||
| Q3 24 | $1.2B | $1.1B | ||
| Q2 24 | $1.2B | $1.3B |
| Q1 26 | — | $3.6B | ||
| Q4 25 | $1.1B | $3.6B | ||
| Q3 25 | $1.1B | $3.3B | ||
| Q2 25 | $1.0B | $3.4B | ||
| Q1 25 | $1.1B | $3.4B | ||
| Q4 24 | $1.2B | $3.5B | ||
| Q3 24 | $1.7B | $3.6B | ||
| Q2 24 | $1.7B | $3.8B |
| Q1 26 | — | — | ||
| Q4 25 | 0.12× | 3.23× | ||
| Q3 25 | 0.12× | 2.70× | ||
| Q2 25 | 0.12× | 2.63× | ||
| Q1 25 | 0.12× | 2.23× | ||
| Q4 24 | 0.15× | 2.13× | ||
| Q3 24 | 0.12× | 2.06× | ||
| Q2 24 | 0.13× | 1.73× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | — |
| Free Cash FlowOCF − Capex | $21.3M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 3.8% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $28.2M | $116.7M | ||
| Q3 25 | $14.0M | $47.5M | ||
| Q2 25 | $6.8M | $34.4M | ||
| Q1 25 | $25.7M | $6.3M | ||
| Q4 24 | $57.9M | $181.1M | ||
| Q3 24 | $23.0M | $52.2M | ||
| Q2 24 | $27.8M | $48.2M |
| Q1 26 | — | — | ||
| Q4 25 | $21.3M | — | ||
| Q3 25 | $7.0M | — | ||
| Q2 25 | $-4.2M | — | ||
| Q1 25 | $19.0M | — | ||
| Q4 24 | $53.1M | — | ||
| Q3 24 | $20.0M | — | ||
| Q2 24 | $21.9M | — |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | — | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | -2.4% | — | ||
| Q1 25 | 11.3% | — | ||
| Q4 24 | 29.6% | — | ||
| Q3 24 | 11.7% | — | ||
| Q2 24 | 12.8% | — |
| Q1 26 | — | — | ||
| Q4 25 | 3.8% | — | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | 6.3% | — | ||
| Q1 25 | 4.0% | — | ||
| Q4 24 | 2.7% | — | ||
| Q3 24 | 1.8% | — | ||
| Q2 24 | 3.4% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | — | ||
| Q2 24 | 15.44× | 1.60× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
BDN
| Rents | $120.7M | 95% |
| Third party management fees, labor reimbursement and leasing | $4.7M | 4% |
